• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jeff Patton Reflects on OCM Performance Period 4 Results, Taking on 2-Sided Risk

Video

Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.

Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.

Transcript

With OCM performance period 4 results now out, how did the results compare with the last 2 performance periods?

So, very similar. Every period we’ve generated savings against the target but every period we’ve not gotten a performance payment. The good news is as it applies to 2-sided risk, that means we would not have had any recruitment, so I think most likely we’re going to go and do 2-sided risk.

What are your thoughts on taking on 2-sided risk?

Risk is risk, so it makes everybody nervous, but with 4 consecutive performance periods where we’re in what we call the safe zone, we have a comfort level. We are investigating stop loss or reinsurance and I’ll have a lot more confidence if I have an insured downside.

Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Dr Ola Landgren
David Awad, PharmD, BCOP
Gordon Crofoot, MD, PA
Jaime Almandoz, MD, MBA
Screenshot of Coral Omene, MD, PhD
Dr Brian Slomovitz
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.